Biogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
|
|
- Paula Montgomery
- 6 years ago
- Views:
Transcription
1 Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009
2 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP FCR-Lumiliximab Relapsed CLL R-Galiximab Relapsed NHL 2
3 RITUXAN Chimeric mab That Binds To and Kills CD20-Expressing Cells Rituxan ADCC Macrophage, monocyte, or natural killer cell FcγRII, FcγRIII CD20 Cell lysis B cell CDC MAC Cell lysis Apoptosis 2009: RITUXAN submissions in Chronic Lymphocytic Leukemia REACH Study: Relapsed CLL CLL8 Study: Frontline CLL Golay et al. Blood. 2000;95:3900; Reff et al. Blood. 1994;83:435; Byrd et al. Blood. 2002;99: ADCC = antibody-dependent cellular cytotoxicity CDC = complement-dependent cytotoxicity
4 REACH and CLL8 Study Design in CLL Screening REACH: Relapsed CLL ~550 patients (First relapse of disease); 90 sites, 17 countries Randomize R-FC x 3 cycles (q 4 weeks) Restage FCR x 3 cycles (q 4 weeks) Binet B,C ~820 patients; (No prior treatment) FC x 3 cycles (q 4 weeks) PD- Off study FC x 3 cycles (q 4 weeks) CLL8: Frontline CLL Screening 4
5 REACH Primary Endpoint: K-M Plot of PFS Proportion Event Free FCR FC Median follow-up 25.3 months Median PFS FC= 21.7 months FCR= 26.6 months HR = 0.76, p=0.02 (IRC) Months since randomization 5
6 CLL8 Primary Endpoint: K-M Plot of PFS Median Follow-up 25.5 Months Median PFS: FC= 32.3 months FCR =42.8 months p=
7 Summary: RITUXAN for the Treatment of CLL REACH Relapsed CLL Median PFS = 21.7 months for FC vs months for FCR (p=0.02 by IRC) CLL8 Frontline CLL Median PFS =32.3 months for FC vs months for FCR (p= ) Both studies significant in both CR and ORR No new or unexpected safety signals consistent with RITUXAN safety profile from other studies MABTHERA (trade name for RITUXAN in the Europe) approved for the front-line treatment of CLL in combination with FC in February 2009 Dual submission of both CLL8 and REACH planned in the US by mid
8 GA101: Third generation anti-cd20 program Preclinical data suggest that GA101 may be better than RITUXAN Increased apoptosis and ADCC Higher affinity for FcγRIIIa receptors In several models, prevents regrowth compared with RITUXAN which temporarily suppresses More effective in depleting B-cells Both degree and duration of depletion in NH primates Goal: Develop a best-in-class anti-cd20 therapy leading to a significant improvement in clinical outcomes for patients with B cell malignancies. 8
9 B Cell Depletion in NH Primates: GA101 vs. RITUXAN 200 Inguinal ( Lymph ) Nodes Abs numbers/mg wt.(x10e3) Vehicle Rituximab (2 x 10 mg/kg) GA101 (2 x 10 mg/kg) GA101 (2 x 30 mg/kg) 0 Baseline Days After Dosing Umana et al., 2007 ASH Meeting, Atlanta, GA 9
10 CD23 and Lumiliximab Mechanism of Action Human constant Regions (IgG1 kappa isotype) Macaque variable regions CD23 Overview CD23 is the low affinity receptor for IgE (FcεRII) Functions to regulate IgE synthesis CD23 is highly expressed and abnormally regulated on CLL cells Lumiliximab is a monoclonal antibody that binds human CD23 with high affinity (Kd = 0.12nM) Lumiliximab Mechanism of Action Predominant MOA is apoptotic cell death via the intrinsic mitochondrial pathway Induces down-regulation of anti-apoptotic proteins including Bcl-2, Bcl-XL, Mcl-1, and XIAP in CLL cells Enhances the apoptotic activity of other anticancer drugs from a number of different classes Adapted from Gould and Sutton Nat. Rev. Immunol
11 Lumiliximab Enhances Apoptosis when Combined with Fludarabine or RITUXAN In Vitro Efficacy (SKW 6.4 cells plus cross-linker) In Vivo Efficacy (disseminated lymphoma SCID mouse model) % Apoptotic Cells Caspase-3 activation (%) Untreated Untreated Isotype Ctrl Isotype Ctrl Lumiliximab Lumiliximab Fludarabine Lumi + Flu RITUXAN Lumi + Ritux Lumiliximab + fludarabine Lumiliximab + RITUXAN Dose (μg/ml) 11 Survival (%) Survival (%) Lumiliximab + Fludarabine Lumiliximab (200 μg) Fludarabine (50 mg/kg) Control Days Following Implant Control Lumiliximab + RITUXAN RITUXAN (200 μg) Lumiliximab (200 μg) Days Following Implant
12 Lumiliximab Clinical Program Lumiliximab Monotherapy Ph 1 dose escalation in Relapsed CLL Well-tolerated at all doses studied Evidence of clinical activity in majority of patients Recommended dose for future studies, 500 mg/m2 At doses 375 mg/m2, CD23 sites on CLL cells were saturated 500 mg/m2 dose resulted in longest duration of receptor saturation No relationship between dose and adverse events Lumiliximab +/- FCR Ph 1/2 and 2/3 (LUCID) in Relapsed CLL; Ph 2 in CLL Frontline (LIFT) Rationale for FCR combination regimen: In vitro and in vivo studies demonstrated improved cytotoxic activity of lumiliximab in combination with fludarabine or rituximab Fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for the treatment of CLL. Ph I/II study demonstrated a 52% complete response (CR) in relapsed CLL, more than twice the CR rate of FCR alone in historical controls, 12
13 Phase II/III, Lumiliximab in Combination With FCR (LUCID) Patient Eligibility (n=900) Relapsed CD23+/CD20+ B-cell CLL 1-2 prior therapies Rai stage III/IV Stage I/II with disease progression Patients not refractory to FC, FR or FCR 6 cycles Lumiliximab + FCR FCR Phase II Complete response endpoint Enrollment complete 390 Pts Phase III Progression-free survival endpoint Strategy for accelerated approval: CR and trend in PFS 13 Note: Study
14 Lumiliximab (anti-cd 23 mab) Molecule Molecular Hypothesis First-in-Class Monoclonal Antibody Targeting CD23 Demonstrated apoptotic cell death as primary MOA and may be potentially effective at overcoming resistance generally seen in CLL Enhanced apoptotic activity in combination with common CLL therapies, fludarabine and rituximab Therapeutic Hypothesis Addition of a well-tolerated pro-apoptotic agent to current SOC treatment will offer greater efficacy without additional toxicity.. Potential Indications Stage Chronic lymphocytic leukemia, small lymphocytic lymphoma Preclinical combination studies ongoing Global Registrational Phase 2/3 trial ongoing in relapsed CLL. Lumiliximab as a critical component of standard therapy, essential for maximizing response and thereby extending longevity and Quality of Life in patients with CLL 14
15 CD80 Expressed on NHL tumor cells Role in Regulating Balance Between Immune Activation and Suppression Background Transmembrane glycoprotein Member of the B7 ligand family (B7.1) 1 Involved in activation and regulation of T- cells 2 Transiently expressed on activated B- cells and antigen presenting cells 3 Plays a role in the regulation and activation of normal and malignant B- cells 1 Therapeutic Hypothesis In addition to direct ADCC-mediated killing of CD80-positive malignant B-cells, galiximab may also inhibit tumor progression by targeting non-malignant, CD80-expressing cells present in the tumor microenvironment (e.g., macrophages, dendritic cells). This may result in an alteration of the cellular composition and/or cytokine profile within the tumour microenvironment that favors inhibition of tumor progression Constitutively expressed on malignant B- cells and Reed-Sternberg cells 4 1. Suvas S et al. J Biol Chem 2002;277: Guinan EC et al. Blood 1994;84: Chambers CA & Allison JP. Curr Opin Cell Biol 1999;11: Munro JM et al. Blood 1994;83:
16 Enhanced Anti-Tumor Activity and Improved Survival in Galiximab Immuno-chemo Combination Therapy SKW disseminated human lymphoma model 100 Gali+Ritux+Doxo Percent Survival Doxo Neg Control IgG1 Doxo injections Antibody injection Ritux Gali + Ritux Ritux + Doxo Days Post Implant Hariharan et al. J Clin Onc 2007;25(18S): abstract 3040; T. Murphy study G-3 16
17 Galiximab Clinical Trials in Lymphoma Relapsed Follicular NHL Monotherapy, Ph I/II in Relapsed Follicular NHL (114-20) Clean safety profile; 4/37 (11%) ORR; Late conversions of PRs to CRs Galiximab + RITUXAN, Ph I/II in Relapsed Follicular NHL (114-21) No increased toxicity; 12.2 month Median PFS compared to 9.4 months for historical RITUXAN monotherapy Galiximab + RITUXAN, Ph III in Relapsed f NHL (114NH301, ongoing) 245 subjects randomized as of March 2, 2009 Galiximab + RITUXAN, Ph III in Relapsed f NHL re-treatment (114NH302, ongoing) Frontline NHL Monotherapy, Ph I (MOA) in Frontline Follicular NHL (114NH103) Galiximab + RITUXAN, Ph II in Frontline f NHL (CALGB-sponsored, 50402, ongoing) Ongoing: 70% ORR, 44% CR/CRU, 12 month DFS 87%; Delayed responses in >15% of PR to CR conversion after 9 mos. of treatment Hodgkin s Monotherapy, Ph II in Relapsed Hodgkin s disease (CALGB-sponsored, 50602, ongoing) 17
18 Phase I/II Galiximab Monotherapy: Study Single Agent Responses Delayed time to best response seen in 4 patients Phase I/II dose-escalating study 4 weekly IV infusions (125, 250, 375, or 500 mg/m2) 37 patients treated (9 received the commercial dose of 500 mg/m2) Overall response rate of 11% (4 of 37 patients) 375 mg/m2 (N = 21): 2 CRs, 1 Baseline Study Month 5 Study Month 12 PR; 500 mg/m2 (N = 10): 1 PR Delayed time to best response seen in the four responders (at 3, 6, 9 and 12 months) Duration of response was 22.7 months 18
19 Efficacy Results (Galiximab + RITUXAN) vs. RITUXAN Event-Free Survival (%) C Ph 1/2 in Relapsed NHL (114-21) Historical Control: RITUXAN monotherapy median EFS = 9.4 mo. Galiximab + RITUXAN median EFS = 12.2 mo Time (Months) Median Age (yrs) Male Stage III/IV Disease Largest Tumor (cm) Median Max # Prior Regimens Median Max RITUXAN Naïve Galiximab + RITUXAN (500 mg/m 2 ) (N=64) % 88 % , , 9 42 % Historical RITUXAN Monotherapy (N=243) % 83 % , , 9 77 % More RITUXAN Naïve in HX control Note: Historic Rituxan EFS data are truncated at 24 months 19
20 TARGET Study (114NH301) Phase III Galiximab + RITUXAN Screening Randomization ~742 patients (First relapse of disease) 4 weekly cycles RITUXAN (375 mg/m2) + placebo RITUXAN (375 mg/m2) + galiximab (500 mg/m2) Follow-up to month 48 Conducted at 220 sites in 28 countries Nearly 250 patients randomized (more than a third of total) Primary endpoint - superiority in PFS with Galiximab + RITUXAN compared with RITUXAN 20
21 Galiximab (anti-cd 80 mab) Molecule Molecular Hypothesis Therapeutic Hypothesis Potential Indications Stage First-in-Class Monoclonal Antibody Targeting CD80 Binding to CD80 induces antibody dependent mediated cellular cytotoxicity (ADCC), synergistic with rituximab Constitutive expression on malignant B-cells and R-S cells Immune mechanisms regulating anti-tumor activity may also contribute to efficacy (APCs and activated B cells) Galiximab will have a role as adjunctive therapy for the treatment of CD80-expressing malignancies including relapsed Follicular Lymphoma based on a direct anti-tumor effect and its unique action on the tumor microenvironment Primary Indication: Relapsed follicular NHL Other: Untreated follicular NHL, DLBCL, Hodgkin s disease Phase 3 Generate rigorous mechanistic and clinical data in support of registration for Relapsed Follicular Lymphoma and establish the rationale for treatment of other CD80 expressing malignancies 21
22 Biogen Idec Oncology Pipeline Oncology RITUXAN Galiximab Lumiliximab Volociximab HSP90 Inhibitors GA101 TYSABRI Anti-IGF-1R Anti-Cripto-DM4 RAF Inhibitor Anti-Fn14 Pre-Clinical Phase 1 Phase 2 Phase 3 Market NHL & CLL (Ph 3 complete, filings 2009) NHL CLL Solid tumors Solid tumors NHL & CLL Multiple Myeloma Solid tumors Solid tumors Solid tumors Solid tumors January 2007 Pipeline 2007 and 2008 Progress 22
23 Biogen Idec Research & Development Day March 25, 2009
Update: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationScottish Medicines Consortium
Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationCOMPANY PRESENTATION. January 2019
COMPANY PRESENTATION January 2019 1 FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise
More informationClinical Pipeline Highlights
Clinical Pipeline Highlights Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 25 MDX-7: Anti-PSMA HuMAb for Prostate Cancer Biology PSMA expressed
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationAntibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma
Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Steven I. Park, MD, 1* and Kristy L. Richards, PhD, MD 1 ABSTRACT Antibody-based immunotherapeutic agents have emerged as important
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationDaratumumab: Uncovering a novel mechanism of action for an approved antibody therapy
Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma
More informationVenetoclax in MCL. Prof. Le Gouill Nantes Medical University, France
Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationBR for previously untreated or relapsed CLL
1 Protocol synopsis Title Rationale Study Objectives Multicentre phase II trial of bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia
More informationCHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma
Media Release Basel, 29 April 2016 CHMP recommends EU approval of Roche s Gazyvaro for people with previously treated follicular lymphoma In the pivotal study, treatment with Gazyvaro plus bendamustine
More informationNASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017
NASDAQ: TGTX J.P. Morgan Healthcare Conference January 2017 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationMedia Release. Basel, 7 November 2013
Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationUBS European Conference 2013
UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth
More informationRituximab, recombinant for intravenous infusion (CAS registry number: ).
MABTHERA Rituximab, recombinant for intravenous infusion (CAS registry number: 174722-31-7). WARNING Use of MABTHERA may be associated with an increased risk of progressive multifocal leukoencephalopathy
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationMedia Release. Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma. Basel, 22 September 2017
Media Release Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationCorporate Presentation
Corporate Presentation October 2018 NASDAQ/TSX: TRIL This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
More informationB Kahl 1, M Hamadani 2, P Caimi 3, E Reid 4, K Havenith 5, S He 6, JM Feingold 6, O O Connor 7
First Clinical Results of ADCT-42, a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate (ADC), in Relapsed/Refractory B-cell Lineage Non-Hodgkin Lymphoma B Kahl 1, M Hamadani 2, P Caimi 3, E Reid
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationNHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationDaratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma
Daratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma Anna Vidal Department of Hemato Oncology IDIBAPS, Barcelona, Spain B cell lymphoid malignancies seen
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationNimotuzumab Paul Keane MD, FRCPC, FACP, FRC Path
Nimotuzumab Paul Keane MD, FRCPC, FACP, FRC Path Research & Development Day Wednesday April 5, 2006 Harvard Club New York City EGFR The EGFR is a member of the ErbB family of tyrosine kinase (TK) receptors
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationCLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationScottish Medicines Consortium
Scottish Medicines Consortium ibritumomab tiuxetan (Zevalin ) No. (171/05) Schering Health Care Ltd 8 April 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationAdvances in haematological malignancies focus on lymphoid disease
Advances in haematological malignancies focus on lymphoid disease Dr Kylie Mason MBBS PhD FRACP FRCPA Haematologist Bone marrow Transplant Physician Clinician Scientist The Royal Melbourne Hospital The
More informationChimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma
Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Stephen J. Schuster, M.D. Director, Lymphoma Program & Lymphoma Translational Research, Abramson Cancer
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationNEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)
NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationFollicular Lymphoma New Agents. Idelalisib
Indolent Lymphoma Workshop Bologna 2017 Follicular Lymphoma New Agents Idelalisib Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Disclosures of Sven de Vos Company name Research support
More informationIl Rituximab nella ITP
Il Rituximab nella ITP Monica Carpenedo U.O.C Ematologia e TMO, Ospedale San Gerardo, Monza Burning questions about Rituximab and ITP What is the mechanism of action? What is long term effect of treatment?
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationMedia Release. Basel, 5 December 2016
Media Release Basel, 5 December 2016 Roche s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan
More informationCopyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationDr. C. Tom Kouroukis. New and upcoming treatments for Lymphoma
Dr. C. Tom Kouroukis New and upcoming treatments for Lymphoma New and upcoming treatments for Lymphoma Dr. Tom Kouroukis Hamilton Convention Centre November 23, 2013 Overview Importance and design of clinical
More information